India is widely recognised as the "pharmacy of the world", with its medicines reaching more than 200 countries. It is also one of the world's largest producers of generic medicines and vaccines.
According to NITI Aayog's Trade Watch, global demand for pharmaceuticals and active pharmaceutical ingredients (APIs) is estimated at around USD 1.3 trillion in 2025, while India's pharmaceutical and API exports stood at USD 35.8 billion.
The figures underline India's growing importance in ensuring the availability of affordable medicines across both developed and emerging markets.
Pharmaceutical exports are a significant source of foreign exchange earnings, support high-value manufacturing and strengthen India's trade profile. Recognising the sector's strategic importance, the government has introduced policy measures such as the Production-Linked Incentive (PLI) scheme to encourage domestic manufacturing and reduce import dependence. These initiatives are helping Indian companies move beyond low-cost generic medicines towards complex formulations, specialty drugs and globally compliant manufacturing.
Weaker Rupee Offers Export Advantage
The depreciation of the Indian rupee is another factor shaping the sector's outlook. Although the currency fell to record lows earlier this year and continues to face pressure from global capital flows and external uncertainties, the trend offers a mixed impact for pharmaceutical companies.
A weaker rupee enhances the price competitiveness of Indian exports in international markets, making domestically manufactured medicines more attractive to overseas buyers. However, it also increases the cost of imported raw materials, specialised equipment and energy-linked inputs, many of which remain essential for pharmaceutical production.
Economists note that India's pharmaceutical competitiveness is no longer based solely on low-cost manufacturing. Instead, it is increasingly driven by the country's scale, manufacturing capabilities, regulatory compliance and reliability as a global supplier.
While currency fluctuations can affect input costs, profit margins and inflation, they do not alter the sector's underlying export strength or its established position in global healthcare supply chains.
Strategic Industry For Long-Term Growth
India's pharmaceutical industry today combines cost efficiency with manufacturing depth, scientific expertise and a trusted supply network. As governments and healthcare providers seek to diversify supply chains following recent global disruptions, India's role is expected to become even more significant.
Beyond being an export success story, the pharmaceutical sector is emerging as a source of economic resilience, strategic influence and long-term industrial growth, reinforcing India's position as one of the world's most important healthcare manufacturing hubs. |
